She survived with ECCT as her Nasal Cancer Treatment when no more option left from hospital

From 2019 to 2022, Mrs. Sri underwent surgery three times and 25 rounds of radiation, yet the nasal cancer she was battling continued to grow, eroding the nasal bones and filling her nasal cavity. Her doctor said surgery was no longer possible. The tumor kept progressing. Her nose was completely blocked, making it impossible to breathe through it. Her voice became coarse, her ears constantly rang, her vision began to blur, and she completely lost her sense of smell. After radiation, she could only consume liquid foods. Her doctor told her: “There’s nothing more we can do.”

Determined to keep going, Mrs. Sri searched for alternative options she could still try. That’s when she found ECCT as the Nasal Cancer Treatment. However, it was not easy for the Medical team to design and configure the device for her specific case. But Mrs. Sri still wanted to try, saying, “Even if this is my last option, I’ll give it a try.”

Due to her condition, her response to treatment was indeed slow — after three months of use, the only noticeable effect was continuous mucus discharge from her nose, with little else being expelled. Progress was relatively slow — her loss of smell and ringing in the ears remained, though she could breathe slightly better through her nose and her nasal-sounding voice had improved.

The nasal discharge continued for six months, gradually decreasing over time. As the mucus lessened, her breathing became easier, she regained the habit of breathing through her nose, her nasal voice almost disappeared, but her sense of smell only returned for very strong odors — she still could not detect faint smells. A CT scan after six months of use showed that the mass in her nasal cavity had almost disappeared — considered remarkably fast for her type of tumour.

The shrinkage of tumors with ECCT largely depends on the clearance of dead cells, which contain high amounts of fat and cholesterol. These components make the tumor hard and fibrous. In Mrs. Sri’s case, because the mass was located in the nasal cavity, the dead cells could drain out directly without much obstruction, even though they contained high fat and cholesterol. This allowed the tumor to shrink relatively quickly.

After 1.5 years of use, almost all of Mrs. Sri’s initial symptoms had returned to normal, except her sense of smell, which was unlikely to fully recover because the nerve endings in her nasal cavity had probably been damaged when the cancer grew there. A CT scan after 1.5 years showed that the tumor mass had not changed but no longer active, suggesting that the remaining tissue had turned into scar tissue.

Now, 3.5 years after starting ECCT — or more than 5 years since her initial diagnosis — Mrs. Sri Lestari is in relatively good health, active, and doing well.